Based on this knowledge attempts have been made to develop immunomodulatory therapy for prevention of cardiovascular disease and pilot vaccines containing apolipoprotein B (apo B) antigens have been shown to significantly reduce atherosclerosis in apolipoprotein E deficient (Apoe-/-) mice [21-23]. This evidence concerns the gene APOE and cardiovascular disorder.